CTRI/2024/02/063149已完成Unknown
A Prescription Event Monitoring (PEM) Study to Evaluate the Effects of Adjuvant Therapy with ZincorespTM Tablets in Patients Having Recurrent Respiratory Disorders and Infections.
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Improvement in symptoms of respiratory disorders and/or infections
研究概览
简要总结
All eligible subjects who meet the inclusion and exclusion criteria will be part of the study.
A detailed history will be obtained from the patients included in the study.
After baseline assessment, patients will be followed-up during the study period (week 1 ± 3 days, and week 2 ± 3 days, week 3 ± 3 days week 4 ± 3 days, week 8 ± 3 days, week 12 ± 3 days]
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Age above 18 years of any gender. 2.Patients who are willing to give consent for the child’s participation in study.
- •Patients having recurrent episodes of any of the following -Fever associated with respiratory tract infections (RTI).
- •URTI (rhinitis, pharyngitis, laryngitis, influenza)- LRTI (pneumonia, bronchitis, and bronchiolitis) -Bronchial asthma -COPD -SARS-CoV-2 -Combined allergic rhinitis and asthma syndrome (CARAS) -Pulmonary tuberculosis.
排除标准
- •1.Any evidence of malignancy.
- •2.History and clinical findings suggestive of metabolic diseases 3.History and clinical findings suggest chronic respiratory tract diseases including interstitial lung disease (ILD) and cystic fibrosis.
- •4.History of respiratory tract surgery.
- •5.Known diagnosis of congenital cardiac defects.
结局指标
主要结局
Improvement in symptoms of respiratory disorders and/or infections
时间窗: Baseline to Week 12
次要结局
- Total number of patients with at least one episode of upper respiratory tract infections (rhinitis, pharyngitis, laryngitis, otitis media, and influenza)(Baseline to Week 12)
- Total number of patients with at least one episode of lower respiratory tract infections (pneumonia, bronchitis, and bronchiolitis)(Baseline to Week 12)
- Total number of patients not having any episode of respiratory tract infections (URTI or LRTI) or exacerbations of existing conditions(Baseline to Week 12)
- Total number of patients with Bronchial asthma, Combined allergic rhinitis and asthma syndrome (CARAS)(Baseline to Week 12)
- Total number of patients experiencing at least one episode of fever during the study period.(Baseline to Week 12)
- Total number of patients requiring antimicrobial agents (antibiotics and antiviral drugs) during the study period.(Baseline to Week 12)
- Total number of patients requiring hospital admission, but not requiring supplemental oxygen during the study period.(Baseline to Week 12)
- Total number of patients requiring hospital admission, requiring supplemental oxygen during the study period.(Baseline to Week 12)
- Number of days of hospitalization required during the study period.(Baseline to Week 12)
- Total number of days of work lost by the patients due to illness during the study period.(Baseline to Week 12)
- Total number of episodes of infections lasting more than 7 days during the study period.(Baseline to Week 12)
- Time required to recover completely from infection during the study period.(Baseline to Week 12)
- Investigator global assessment for efficacy(Week 12)
- Investigator global assessment for safety and tolerability(Week 12)
- Patient global assessment for efficacy(Week 12)
- Patient global assessment for safety and tolerability(Week 12)
研究者
Dr Vaishali Thakare
D. Y. Patil Deemed to be University, School of Medicine, Navi Mumbai
研究点 (1)
Loading locations...
相似试验
已完成
Unknown
The Effects and safety of ZincorespTM Tablets/ Syrup in Patients Having Ear, Nose, Throat and Respiratory Disorders and Infections.CTRI/2024/02/063092apex laboratories private Limited500
已完成
Unknown
To Effects of ZincorespTM Syrup in Children Aged 2- 12 Years Having Respiratory Disorders and Infections.CTRI/2024/02/063048apex laboratories private limited500
尚未招募
Unknown
Prescription Event Monitoring Study of Emrok tab. and Emrok IV to evaluate the safety and efficacy in the patients who have bacterial infections.CTRI/2024/09/073689Wockhardt Ltd30,000
尚未招募
Unknown
Prescription event monitoring study of Emrok injection and tab in the patient of diabetes foot ulcer.CTRI/2024/04/065615Wockhardt Ltd7,500
尚未招募
Unknown
Real world study to evaluate the safety and efficacy of NUWOK tab and Injection in the patients have infection.CTRI/2024/04/065903Wockhardt Ltd10,000